Communique Kiev

The ONCOGENE^® company has presented MH Guide^® Medical Report, designed for medical oncologists to support decision-making when selecting targeted therapies (Kyiv, Ukraine)

The rapid development of fundamental and applied molecular biology area in oncology, huge array of biomedical and pharmacological data, knowledge (big data) and software capabilities to process them, there is a real possibility of clinical interpretation of genomic data arrays of cancer patients. The company operates with a dedicated interactive service ONCOGENE^® , providing to medical oncologists possibility of clinical interpretation of the genomic profile of solid malignant tumor of patients to support the best clinical decision-making when selecting potentially effective and safe protocols on anticancer drug treatment.

Medical reports are generated using a diagnostic device (software) MH Guide^® (CE-IVD), registered in Europe, which is intended for clinical interpretation of genomic data of patient's tumor, and obtained as a result of whole-exome sequencing of DNA tumor. MH Guide^® is associated with Dataome^® – the world’s largest cloud technology platform (proprietary knowledge base), intended for collection, processing, integration and analysis of the structured and unstructured world medical, biological and pharmacological data with the highest quality, amount, diversities, novelty, relevance, safety and utility in real time.

In this context, a local conference was held in Chisinau, November, 11th under the theme „New Strategies in Personalized Medicine for Solid Tumors: Whole exome sequencing”. It was attended by around 60 oncologists of the Kiev City Clinical Oncology Center, Kiev, Ukraine . Prof. Alexandr Mustya has presented the clinical application of MHGuide ® and its role in the decision-making process for cancer patients, University Hospital Bonn, Germany.

During the presentation Prof. Alexander Mustea highlighted the role of personalized medicine and molecular diagnostics in clinical practice and the evaluation of characteristics of MHGuide^® Report. As well were presented specific requirements for a tumor sample. Afterwards, Molecular Health overview was presented by Dr. Matthias Kopf. These presentations opened the floor for a highly interactive discussion between the oncologists and Prof. Alexander Mustea who shared his personal clinical experience.

Such an exchange of experience left Ukrainian oncologists more confident in what should a medical oncologist focus on when choosing targeted therapy, given that genomic profiling is a promising perspective in cancer management.